Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non‐small cell lung cancer

Zhao, Qian; Li, Butuo; Xu, Yiyue; Wang, Shijiang; Zou, Bing; J, Yu; Wang, Linlin

doi:10.1002/cam4.4171

Cited by 15 publications

(10 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective cohort study (Ge et al 2020 ) reported that males, squamous histology, no brain or liver metastases, any age, not beyond ≥ the third treatment line, with PR to the previous ICI, and monotherapy as previous ICI can benefit more from ICI rechallenge compared with other treatment. For initial immunotherapy, patients with smoking exposure (Kim et al 2017 ; Zhao et al 2021 ), better ECOG PS (Zhao et al 2021 ), higher PD-L1 expression (Duchemann et al 2021 ), and absence of liver metastasis (Zhao et al 2021 ) benefited more from the treatment. Theoretically, previous treatment lines and response to initial immunotherapy can lead to various efficacy of ICI rechallenge.…”

Section: Discussionmentioning

confidence: 99%

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study

Hao

Yang

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose After progression to immunotherapy, the standard of care for non-small cell lung cancer (NSCLC) was limited. Administration of the same or different immune checkpoint inhibitors (i.e., ICI rechallenge) may serve as a novel option. The present study aimed to evaluate the efficacy of ICI rechallenge for NSCLC and explore prognostic factors. Methods In this retrospective cohort study, data of advanced or metastatic NSCLC patients rechallenged with ICI at the Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College between December 2018 and June 2021 were retrieved. Progression-free, overall survivals (PFS; OS), etc. were calculated. Subgroup analyses were conducted according to baseline characteristics, prior treatment results, etc. for prognostic factor exploration using the Cox model. Results Forty patients were included. Median age was 59 years. Thirty-one (78%) were male. Twenty-seven (68%) were smokers. Adenocarcinoma (28 [70%]) was the major histological subtype. Median PFS of patients receiving initial ICI was 5.7 months. The most common rechallenge regimens were ICI plus chemotherapy and/or angiogenesis inhibitor (93%). Seventeen (43%) were rechallenged with another ICI. Median PFS for ICI rechallenge was 6.8 months (95% CI 5.8–7.8). OS was immature. Tendencies for longer PFS were observed in nonsmoker or patients with adenocarcinoma, response of stable/progressive disease in initial immunotherapy, or whose treatment lines prior to ICI rechallenge were one/two. However, all results of prognostic factors were nonsignificant. Conclusion ICI rechallenge may be an option for NSCLC after progress to immunotherapy. Further studies to confirm the efficacy and investigate prognostic factors are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study

Hao

Yang

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…NLR and dNLR can be utilized as novel biomarkers to determine the inflammation/immunity ratio in a plethora of solid tumors, and elevated NLR value is associated with lymphocytopenia and neutrophilia 28 . It is noteworthy that lymphocytes not only exert key roles in recognizing and killing diverse tumors but also assist ICIs in showing antitumor functions 29 . The elevated LDH is indicative of hypoxia-induced increase in tumor necrosis and tumor glycolytic activity and LDH level is inversely correlated with the response to ICIs and probably triggers hyperprogressive disease 30 .…”

Section: Discussionmentioning

confidence: 99%

“…In addition, LDH can accelerate resistance to systemic therapy through the facilitation of immune escape and immune suppression 36 . The correlation of high LDH levels with poor prognosis in patients treated with ICIs is possibly due to the accumulation of serum tumor-derived lactic acid, which makes the CD8 T cells unable to export lactate and thus causes metabolic disorders, and indeed, dysregulation of T-cell metabolism is perhaps another regime of tumor resistance to various ICIs 29 . The LIPI score, combining dNLR and LDH, shows promising utilization value as a prognostic biomarker in NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Correlation of Lung Immune Prognostic Index With Efficacy of PD-1/PD-L1 Inhibitor Combined With Chemotherapy and Prognosis in Patients With Advanced Non–Small Cell Lung Cancer

Zhu,

Zhang

2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: Non–small cell lung cancer (NSCLC) is a devastating but universal class of lung carcinoma with an unfavorable prognosis. This paper mainly investigated the correlation between lung immune prognostic index (LIPI) score and combined treatment of immune checkpoint inhibitor and chemotherapy (CHT) in patients with advanced NSCLC. Methods: Totally, 301 advanced NSCLC patients with programmed death-ligand 1 (PD-L1) expression ≥1% were assigned into good LIPI group (N=113), intermediate LIPI group (N=101), and poor LIPI group (N=87) based on LIPI scoring system, followed by treatment of CHT plus programmed cell death-1 (PD-1)/PD-L1 inhibitor. The differences in clinical parameters between subgroups of NSCLC patients were analyzed by χ2 test, 1-way analysis of variance, and Kruskal-Wallis H test. All patients were followed up until June 30, 2022, and objective response rate, disease control rate, progression-free survival (PFS), and overall survival (OS) were recorded. The independent associations of LIPI score with PFS and OS were assessed via the Cox regression model. Results: There were evident differences in clinical stage and lymphocyte among the 3 subgroups of NSCLC patients. The efficacy of PD-1/PD-L1 inhibitor combined with CHT was better in patients with good LIPI score, manifested by higher objective response rate and disease control rate. Moreover, LIPI score was an independent factor influencing PFS and OS in patients with advanced NSCLC, with longer PFS and OS in patients with good LIPI score. Conclusion: LIPI score has a predictive value for combination therapy of PD-1/PD-L1 blockade and CHT in advanced NSCLC patients.

show abstract

“…However, identifying the patient cohort that will benefit from immunotherapy remains a pressing problem to be addressed. Previous studies have explored the prediction of immunotherapy efficacy from multiple perspectives, such as drug-based score ( 12 ), lung immune prognostic index (LIPI) ( 13 ), smoking ( 14 ), liver metastasis ( 15 ), lactate dehydrogenase (LDH) ( 16 , 17 ), tumor mutational burden (TMB) expression ( 18 ), neutrophil-to-lymphocyte ratio (NLR) ( 19 , 20 ), modified lung immune predictive index (mLIPI) scores ( 21 ), and so on. Despite achieving some results, the existing literature does not completely solve the problem of predicting immunotherapy efficacy.…”

Section: Introductionmentioning

confidence: 99%

Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study

Hu¹,

Jin²,

Niu³

et al. 2022

J Thorac Dis

View full text Add to dashboard Cite

Background: At present, there is no accurate biomarker for immune checkpoint inhibitors (ICIs). Since the efficacy of ICIs is associated with a variety of indicators, establishing a model to predict its efficacy is more clinically significant and in line with clinical needs. Methods: We collected and retrospectively analyzed the relationship between immunotherapy efficacy and clinicopathologic features in lung adenocarcinoma patients treated with ICIs. Progression-free survival (PFS) and overall survival (OS) were analyzed. Univariate and multivariate Cox proportional hazards regression analyses were conducted to identify prognostic factors associated with PFS. Besides, a clinical prediction model was established based on the results of the multivariate Cox regression analyses to predict PFS.Results: A total of 201 lung adenocarcinoma patients treated with ICIs were assessed. Univariate analysis showed that male gender [hazard ratio (HR) =0.

show abstract

Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non‐small cell lung cancer

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 15 publications

References 54 publications

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study

Correlation of Lung Immune Prognostic Index With Efficacy of PD-1/PD-L1 Inhibitor Combined With Chemotherapy and Prognosis in Patients With Advanced Non–Small Cell Lung Cancer

Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study

Contact Info

Product

Resources

About